Literature DB >> 4066874

Gas chromatographic-mass spectrometric analysis of methylphenidate and p-hydroxymethylphenidate using deuterated internal standards.

K S Patrick, K R Ellington, G R Breese, C D Kilts.   

Abstract

A gas chromatography-mass spectrometry assay is described for the simultaneous determination of threo-dl-methylphenidate and threo-dl-p-hydroxymethylphenidate in plasma and urine using selected ion monitoring of electron impact generated fragments of their pentafluoropropionyl derivatives. The use of recently available deuterated analogues as internal standards improves overall performance relative to previous methods. The practical limit of quantifiable detection of the assay is 0.5 ng/ml for both methylphenidate and p-hydroxymethylphenidate. p-Hydroxymethylphenidate appears to be a significant urinary metabolite of methylphenidate in rats but not in humans.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4066874     DOI: 10.1016/s0378-4347(00)84601-0

Source DB:  PubMed          Journal:  J Chromatogr


  7 in total

1.  Bioequivalence of methylphenidate immediate-release tablets using a replicated study design to characterize intrasubject variability.

Authors:  M C Meyer; A B Straughn; E J Jarvi; K S Patrick; F R Pelsor; R L Williams; R Patnaik; M L Chen; V P Shah
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

2.  Enantiospecific determination of DL-methylphenidate and DL-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: application to human ethanol interactions.

Authors:  Hao-Jie Zhu; Kennerly S Patrick; John S Markowitz
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-02-25       Impact factor: 3.205

3.  Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics.

Authors:  K S Patrick; A B Straughn; R R Minhinnett; S D Yeatts; A E Herrin; C L DeVane; R Malcolm; G C Janis; J S Markowitz
Journal:  Clin Pharmacol Ther       Date:  2007-03       Impact factor: 6.875

Review 4.  Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.

Authors:  J S Markowitz; K S Patrick
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping.

Authors:  Natalie L LeVasseur; Hao-Jie Zhu; John S Markowitz; C Lindsay DeVane; Kennerly S Patrick
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-12-04       Impact factor: 3.205

6.  A novel HPLC fluorescence method for the quantification of methylphenidate in human plasma.

Authors:  Hao-Jie Zhu; Jun-Sheng Wang; Kennerly S Patrick; Jennifer L Donovan; C Lindsay DeVane; John S Markowitz
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-08-19       Impact factor: 3.205

7.  Development of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primates.

Authors:  Xiaoxia Yang; Suzanne M Morris; Jeffery M Gearhart; Christopher D Ruark; Merle G Paule; William Slikker; Donald R Mattison; Benedetto Vitiello; Nathan C Twaddle; Daniel R Doerge; John F Young; Jeffrey W Fisher
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.